Taiwan Primo Biotechnology Co., Ltd.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
Primo’s products and services include radioligand therapeutic agents, tumor‑molecular imaging diagnostics (such as PB01 / [¹⁸F]PSMA‑1007 for prostate cancer), and imaging‑platform plus manufacturing services supporting clinical trials. The company has als
The content above was translated by Ai
Founded Year
2021
Unified Business No.
90712775
Status
Active
Number of Employees
0
Total Paid-in
Capital
666,760,228 (NT$)
Location of Company
Taiwan
, Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Primo Biotechnology Co., Ltd., headquartered in Taipei, focuses on the development and manufacturing of precision medicine and radioligand theranostics (RLT). The company is committed to leveraging molecular imaging and radiopharmaceutical technologies to improve cancer diagnostics and therapy, with the vision "Future in Precision."
The content above was translated by Ai
